Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-11

Study Completion Date

2021-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the safety and tolerability of the AKST1210 column at blood-flow rates greater than 250 mL/min in subjects with end-stage renal disease (ESRD) undergoing hemodialysis (HD). The study will assess the safety, tolerability, and impact on HD parameters when the AKST1210 column is used at a blood-flow of up to 450 mL/min.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Conventional Dialysis and the Allient System

NCT00788905

End Stage Renal Disease Chronic Kidney Failure

UNKNOWN NA

AST-120 in Hemodialysis Patients With Uremic Pruritus

NCT04639674

Uremic Pruritus

COMPLETED PHASE4

A Comparative Study of Two Kinds of Hemodialysis Filters

NCT05899283

Uremia

COMPLETED NA

Gambro AK200 ULTRA Hemodiafiltration Study

NCT01202708

Chronic Renal Failure

COMPLETED NA

Evaluating the Use of the Qidni/D Hemodialysis System by Subjects With End-Stage Renal Disease

NCT06086470

Kidney Disease, End-Stage

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label study in approximately 12 to 15 subjects between 40 and 75 years of age with ESRD on HD. The objective of this study is to explore the safety and tolerability of the AKST1210 column at blood-flow rates greater than 250 mL/min in subjects with ESRD undergoing HD. The proposed study will assess the safety, tolerability, and impact on HD parameters when the AKST1210 column is used at a blood-flow rates of up to 450 mL/min. Each participant, per the protocol, will be sequentially treated to each column and blood-flow rate combination.

The incidence of IDH events will be one factor used to determine column size/blood-flow rate escalation/de-escalation as well as discontinuation from the study. The planned duration of subject participation is approximately 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End-Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AKST1210 device

AKST1210 column will be connected in series for the duration of each hemodialysis session.

Group Type EXPERIMENTAL

AKST1210 S-15 at 250 mL/min

Intervention Type DEVICE

Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 250mL/min

AKST1210 S-15 at 450 mL/min

Intervention Type DEVICE

Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 450mL/min

AKST1210 S-25 at 250 mL/min

Intervention Type DEVICE

Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 250mL/min

AKST1210 S-25 at 450 mL/min

Intervention Type DEVICE

Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 450mL/min

AKST1210 S-35 at 250 mL/min

Intervention Type DEVICE

Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 250mL/min

AKST1210 S-35 at 450 mL/min

Intervention Type DEVICE

Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 450mL/min

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AKST1210 S-15 at 250 mL/min

Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 250mL/min

Intervention Type DEVICE

AKST1210 S-15 at 450 mL/min

Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 450mL/min

Intervention Type DEVICE

AKST1210 S-25 at 250 mL/min

Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 250mL/min

Intervention Type DEVICE

AKST1210 S-25 at 450 mL/min

Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 450mL/min

Intervention Type DEVICE

AKST1210 S-35 at 250 mL/min

Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 250mL/min

Intervention Type DEVICE

AKST1210 S-35 at 450 mL/min

Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 450mL/min

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

S-15 at 250 mL/min S-15 up to 450 mL/min S-25 at 250 mL/min S-25 at 450 mL/min S-35 at 250 mL/min S-35 at 450 mL/min

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females aged 40 - 75 years, inclusive.
2. End Stage Renal Disease (ESRD) requiring HD.
3. Dialysis vintage ≥ 24 months.
4. Absence of clinically-relevant residual renal function.
5. Regular Hemodialysis (HD) sessions done at blood-flow rates between 400 and 500 mL/min, and with inter-dialysis intervals of 48 hours or more.
6. Stable health status for at least 4 weeks prior to screening based on medical history, and findings from physical examination, laboratory tests, vital signs, and ECG, as assessed by the investigator.
7. Life expectancy \> 6 months (as determined by the investigator).
8. Body mass index (BMI) between 18 and 37 kg/m2, inclusive, with a minimum body weight of 52 kg.
9. Must be on stable doses (\> 4 weeks) of all treatments for concomitant diseases (e.g., diabetes, hypertension), but this does not apply to medications for conditions related to ESRD (e.g., medications for calcium and phosphate control, anemia).
10. Must be able to follow the study protocol and receive the treatment in the established timeframe.
11. Must provide a signed and dated informed consent form.

Exclusion Criteria

1. Patients for whom adequate anticoagulation cannot be achieved, such as those with severe anemia, severe hemorrhagic diathesis, severe gastrointestinal ulcers, or who are receiving anticoagulant medications for any reason other than as required for HD. Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is allowed.
2. Patients for whom extracorporeal circulation therapy is contraindicated, such as those with severe cardiac insufficiency, acute myocardial infarction, severe cardiac arrhythmia, acute seizure disorder, or severe uncontrolled hypertension.
3. Patients with Kt/V \< 1.2 during recent 8-week period prior to run-in.
4. History of hypersensitivity to heparin, including heparin-induced thrombocytopenia.
5. History of hypersensitivity to the AKST1210 column or its components.
6. Patients who are not anticipated to be able to tolerate blood-flow rates of 450 mL/min during HD (e.g., new vascular access that cannot be used with 14G or 15G needles).
7. Patients who are at higher risk for intradialytic hypotension (IDH) including:

1. Medical records indicating the occurrence IDH (SBP \< 90 mmHg) in more than 30% of HD sessions during a recent 8-week period prior to run-in;
2. Patients requiring or expected to require extensive fluid management as determined by the investigator;
3. Presence of pre-dialysis hypotension, defined as SBP \< 90 mmHg and/or diastolic blood pressure (DBP) \< 50 mmHg, before any of the last 3 dialysis sessions prior to screening;
4. Diagnosis of IDH in medical records;
5. Diagnosis of autonomic dysfunction;
6. Patients who frequently require a ultrafiltration rate (UFR) above 13 mL/kg/h.
8. Patients who are pregnant or breast-feeding or who are planning to become pregnant. Female subjects must not be pregnant or breastfeeding. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and prior to start of treatment. WOCBP and men must agree to use highly-effective contraception (Clinical Trial Facilitation Group 2014) prior to study entry. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menses for at least 2 years without an alternative cause). Should a woman become pregnant or suspect she is pregnant while she or her male partner is participating in the study, she should inform her treating physician immediately.
9. Clotting disorders.
10. Sickle cell anemia, hereditary spherocytosis, or autoimmune hemolysis.
11. Clinically significant abnormalities on screening ECG including QT interval corrected for heart rate (QTc) using Fridericia's correction formula \[QTcF\] of ≥ 500 ms in men and ≥ 520 ms in women.
12. Delirium (encephalopathy).
13. Out of range value for complete blood count (CBC), complete metabolic panel, or coagulation that the investigator deems clinically significant.
14. Thyroid stimulating hormone (TSH) below 0.2 or above 6.0 milli-International unit (mIU)/L, and/or clinically-relevant abnormalities in T3 or T4.
15. Hemoglobin level \< 9.0 g/dL.
16. Alanine aminotransferase (ALT) and/or aspartate transaminase (AST) \> 3 times upper limit of normal.
17. Uncontrolled type 2 diabetes.
18. Concurrent or have recent participation in another interventional clinical trial. Prior clinical trial subjects must have discontinued investigational agents/devices at least 30 days prior to planned first use of the AKST1210 column.
19. History of severe depression/suicidality requiring hospitalization in the last 6 months.
20. Significant drug or alcohol abuse within the past 12 months.
21. Patients planning to receive renal transplantation during the study.
22. Patients with any other condition and/or situation the investigator believes may interfere with the safety of the subject during study participation, study conduct, or interpretation of study data.

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No